Author: Ravi Shankar

Proposed Cash Acquisition Expands Treasure Global into AI-Enabled Smart Utility Infrastructure

KUALA LUMPUR, Malaysia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company focused on AI-powered enterprise solutions and digital transformation, today announced that it has signed a non-binding memorandum of understanding (“MOU”) with Mestiz Holding Berhad (“MHB”) for the proposed US$38 million cash acquisition of a 51% controlling interest in Mestiz Century Logic Sdn Bhd (“MCL”), a Malaysia-based provider of cloud-based smart water metering technology and digital water management solutions.

Under the MOU, MHB has granted Treasure Global a 120-day exclusivity period to conduct due diligence on MCL and negotiate the terms of a definitive agreement. Completion of the proposed acquisition remains subject to the execution of a definitive agreement and customary closing conditions, including satisfactory completion of due diligence and receipt of required regulatory and board approvals.

MCL specializes in smart water metering solutions powered by cloud computing and Internet of Things (“IoT”) technology. Its smart meters are designed to deliver up to four times the accuracy of conventional mechanical meters, while providing enhanced durability and digital connectivity.

MCL’s smart metering platform further integrates artificial intelligence to support real-time consumption monitoring, remote meter reading, leak detection and predictive maintenance, enabling utilities to improve operational visibility and transition toward more intelligent, data-driven water management.

“Smart water metering represents a significant diversification opportunity for Treasure Global,” said Sam Teo, Acting Chief Executive Officer of Treasure Global. “MCL’s cloud-based, IoT and AI-enabled technology addresses a growing need among utilities to modernize aging water infrastructure, improve billing accuracy and reduce water loss. We believe intelligent metering, real-time data and predictive analytics can create meaningful operational value while supporting more efficient and data-driven water management.”

The proposed acquisition comes amid continued global growth in smart water infrastructure. According to Fortune Business Insights, the global smart water meter market is estimated at approximately US$6.02 billion in 2026 and is projected to reach approximately US$14.74 billion by 2034, representing a compound annual growth rate of approximately 11.85% over the forecast period.

If completed, the proposed acquisition would mark Treasure Global’s entry into the smart utility infrastructure sector, expanding the Company’s technology portfolio beyond digital payments and enterprise AI. The transaction would provide Treasure Global with exposure to a growing smart-metering market while supporting its strategy of building diversified, technology-driven revenue streams and long-term shareholder value.

About Treasure Global:
Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of March 31, 2026, ZCITY has attracted 2.71 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations, assumptions, and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements typically include terminology such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” or similar expressions.

Factors that could cause actual results to differ materially include, without limitation, the parties’ ability to negotiate and execute a definitive agreement; satisfactory completion of due diligence; completion of the proposed acquisition; the Company’s ability to integrate MCL and realize anticipated strategic benefits; adoption and performance of MCL’s smart water metering technology; customer and utility demand; regulatory and procurement requirements; technology performance; cybersecurity and data privacy risks; competition; and changes in economic, infrastructure and market conditions.

The forward-looking statements in this press release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT
Investor and media contact:
Investor Relations Team
Treasure Global
ir_us@treasureglobal.org

Investment increases production capacity, supports booming consumer demand and reinforces Wisconsin’s leadership in dairy biosolutions

WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) — Novonesis, a global leader in biosolutions, announced the completion of a major expansion at its West Allis, Wisconsin production facility. The investment increases the company’s North American production capacity for dairy cultures, boosting fermentation capacity by approximately 66% and packaging capacity by 17%, while establishing West Allis as one of the world’s largest lactobacillus production facilities. The additional capacity will allow Novonesis to help customers keep pace with booming consumer demand for more nutritious foods without compromising taste, texture or quality, while reinforcing Wisconsin’s role as a leader in dairy manufacturing and innovation. 

“For nearly a century, West Allis has played an important role in helping advance dairy innovation,” said Theis Bacher, Senior Vice President, Food & Beverage, Novonesis North America. “Today, it serves as our North American center of excellence for food cultures. This expansion builds on that legacy, strengthening our ability to continue delivering the biosolutions our customers rely on while investing in the people, manufacturing capabilities and technology that will help shape the future of dairy. By enabling dairy manufacturers to produce nutritious, high-quality foods more efficiently and sustainably, we’re helping advance healthier living through biology.” 

“This investment is also a commitment to the West Allis community, reinforcing our dedication to providing high-quality, high-performing cultures to customers in Wisconsin and around the world,” said Anders Lund, Chief Operating Officer and Executive Vice President, Novonesis. “As ‘America’s Dairyland,’ Wisconsin takes great pride in its dairy heritage, and we are proud to be a leader in culture ingredients that support dairies and food manufacturers from farm to fork.” 

While the current expansion adds new jobs and significant production capacity, the site layout allows for additional growth over time by leveraging existing infrastructure along with automation and robotics. The project also incorporates energy-efficient equipment, water reuse, and waste heat recovery to reduce the environmental footprint of operations. Together, these enhancements expand Novonesis’ ability to produce the biosolutions food manufacturers rely on every day, helping customers improve how food is produced while supporting a more efficient, resilient bioeconomy. 

From the cultures used to make cheese and yogurt to innovations that help manufacturers improve product quality, reduce waste and operate more efficiently, Novonesis’ biosolutions help make nutritious dairy foods more accessible while supporting a more sustainable food system and advancing healthier lives on a healthier planet. 

“Wisconsin’s dairy leadership has always been built on the combination of tradition and innovation,” said John Umhoefer, executive director of the Wisconsin Cheese Makers Association. “Investments in advanced dairy manufacturing capabilities help strengthen the infrastructure our cheesemakers rely on, support skilled jobs and reinforce Wisconsin’s ability to remain at the forefront of dairy production. Novonesis’ continued investment in West Allis is another example of the innovation happening across our state’s dairy industry.” 

The West Allis site opened in 1929 and has long been part of Wisconsin’s dairy industry. Today, the facility employs 360 people and supplies cultures to dairy manufacturers across North America. The completion of the expansion marks another milestone in the site’s nearly century-long history of supporting dairy innovation and manufacturing.  

Novonesis celebrated the completion of the expansion with a ribbon-cutting ceremony attended by customers, employees, community leaders and industry partners.  Guests toured the expanded production facility and customer experience center, highlighting the technologies and capabilities that will support the next generation of dairy manufacturing. 

About Novonesis 

Novonesis is a global biosolutions company leading the era of biosolutions. By leveraging the power of microbiology with science, Novonesis transforms the way the world produces, consumes, and lives. Across more than 30 industries, Novonesis biosolutions are already creating value for thousands of customers while benefiting the planet. With more than 11,000 employees worldwide, Novonesis partners with businesses and communities to better our world with biology. 

Attachments

• West Allis Ribbon Cutting
• West Allis Ribbon Cutting

CONTACT: Kathy Humphrey
Novonesis
19193397110
Khp@novonesis.com

• Expansion benefits families, remote work, gaming, streaming, agriculture, telehealth
• In celebration, Kinetic to host free community festivities Sept. 28 – Oct. 5

CHARLOTTE, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Kinetic, the leading residential and business insurgent fiber internet provider, announced today that it increased its fiber network in the greater Concord area by nearly 23% in the last year.

Kinetic added more than 7,800 new fiber locations in the community, surpassing a major milestone of more than 38,000 homes passed. This expansion is fully funded by Kinetic and highlights the company’s commitment to this community and is a signal of future growth and opportunity across the region.

“Concord is a key market for Kinetic and an important link in the region’s growing technology corridor,” said Stacy Hale, Kinetic’s state operations president. “In honor of surpassing this milestone, it’s time that we celebrate. And to the residents of this area, know that we’re not done yet; we’ll continue adding more fiber locations and will remain a long-term partner to this community.”

Fast Forward: Concord — a Free Community Celebration
To celebrate this milestone, Kinetic will host a week of free events for the community.

Planned week highlights

• Tuesday, Sept. 29: Kinetic employees will volunteer at the Sonshine Backpack Ministry, a nonprofit program that provides weekly food bags to school aged children that face food insecurities.
• Thursday, Oct. 1: Kinetic will host a free technology, internet and security course from 10:30 – 11:15 a.m. at the Kannapolis VFW Post 8989 for those who need a more hands-on experience with tech.  
• Friday, Oct. 2: Concord Fiber Night Lights, where Kinetic will give away swag items at the Central Cabarrus vs Cox Mills high school football game starting at 7 p.m. While supplies last.
• Saturday, Oct. 3: Kinetic will have a booth at the Concord International Festival in Downtown Concord from noon to 6 p.m. Stop by for family fun and free swag items.

Why Kinetic’s fiber infrastructure matters to North Carolina
Fiber is the best technology for the long-term success of Concord’s communications needs. Research shows that fiber-connected communities experience 213% higher business growth, 10% higher self-employment and a potential 14-17% increase in home values. Fiber is also significantly more sustainable than copper and uses up to 95% less energy per gigabit. It requires less maintenance over time, which reduces environmental impact and community disruption.

As a long-term partner to the Concord community, Kinetic Is committed to delivering on its promise to provide fast, reliable, future-proof connectivity that helps local economic growth, education, telehealth, and small business competitiveness. This investment underscores the company’s dedication to providing the communities it serves—the same communities its employees also live and work in—with sustained value both now and for years to come.

Kinetic, which was also named CNET’s Best Rural Fiber Internet Provider in 2026, is rooted in North Carolina and is proud to serve its communities beyond internet connectivity. Kinetic’s fiber expansion milestone in Concord follows the company recently reaching 2 million homes passed with fiber internet across its 18-state footprint.

Residents who want to check fiber availability or construction updates can call 1- 877-90-FIBER (877-903-4237) or visit www.gokinetic.com.

About Kinetic: Named the 2026 Telecommunications Company of the Year (Stevie GOLD/American Business Awards), Kinetic is a business unit of Uniti (NASDAQ: UNIT), and is a premier insurgent provider of multi-gigabit fiber internet, whole-home Wi-Fi, internet security, and voice services in 1,400 markets across 18 states in the Southwestern, Southeastern, Midwestern, and Northeastern U.S. Additional information is available at gokinetic.com.

Media Contact
Victoria Carman
uniti.kinetic.pr@uniti.com

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study

Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026

FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer (“mCRC”).

Nearly all planned clinical sites for Part A of REO 033 have now been activated, and multiple patients are currently enrolled (link to study on ClinicalTrials.gov). With the site activation process largely complete, the Company is focused on accelerating enrollment and generating randomized clinical data evaluating the contribution of pelareorep to the current standard-of-care regimen.

REO 033 is a randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan (“FOLFIRI”) and bevacizumab versus FOLFIRI and bevacizumab in patients with second-line RAS-mutant MSS mCRC. Part A is expected to enroll approximately 60 patients randomized between the two treatment arms, with objective response rate (“ORR”) as the primary endpoint, and progression-free survival (“PFS”), overall survival (“OS”), safety, and biomarker analyses among the additional endpoints.

“We are seeing strong momentum in REO 033 now that substantially all of our planned sites are open and multiple patients are on study,” said John McAdory, Chief Operating Officer of Oncolytics. “Given the current pace of enrollment, we expect to have the ability to report interim data from Part A by year-end, based on the number of evaluable patients enrolled by the end of October. Importantly, with site activation substantially behind us, our focus is now squarely on enrollment, execution, and generating the randomized clinical data that can inform the next stage of the program.”

REO 033 Builds on Encouraging REO 022 Clinical Data

REO 033 was designed to prospectively evaluate the efficacy signals previously observed in REO 022 in a randomized setting. In REO 022, pelareorep in combination with FOLFIRI and bevacizumab demonstrated encouraging ORR, PFS, and OS compared with historical second-line benchmarks:

Efficacy Measure	REO 022: Pelareorep + FOLFIRI + Bevacizumab1	Historical Second-Line Benchmark
Objective Response Rate	33%	~6–11%2, 3
Median Progression-Free Survival	16.6 months	~5.7 months2
Median Overall Survival	27.0 months	~11.2 months2
Median Duration of Response	19.5 months	~4–6 months4

The REO 022 results were generated in a small, non-randomized study, and cross-study comparisons have inherent limitations. REO 033 is designed to test the pelareorep regimen prospectively against a concurrent control arm and determine whether the efficacy signals observed in REO 022 can be replicated in a randomized study.

Potential Registration Path Aligned with the Food and Drug Administration

The Company recently aligned with the U.S. Food and Drug Administration (the “FDA”) on the concept for a potential pivotal Part B expansion of REO 033.

Under the proposed regulatory strategy, Part B would build directly upon the ongoing randomized REO 033 study and could support a potential accelerated approval submission based on objective response rate, with progression-free survival providing the basis for potential full approval.

The Company expects data from Part A to inform the final size and execution of the potential pivotal Part B expansion.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

References

1. Goel S, et al. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. Mol Cancer Ther. 2020 May;19(5):1148-1156. doi: 10.1158/1535-7163.MCT-19-1117.
2. Bennouna J. Lancet Oncol (14):29-37, 2013
3. Iwamoto S. Ann Oncol. Jul;26(7):1427-33, 2015
4. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C–mutated colorectal cancer. Published June 21, 2024. Accessed April 28, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include those regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; the timeline and outcome of interim data from Part A of REO 033; the results of the proposed regulatory strategy and approval of Part B of REO 033; the Company’s belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com

AS Inbank has decided to prematurely redeem the Additional Tier 1 bonds issued on 1 November 2021, registered under ISIN code EE3300002286 (hereafter: Inbank AT1 Bonds).

The early redemption will be carried out in accordance with the terms and conditions of the Inbank AT1 Bonds, which permit full or partial early redemption after 1 November 2026, provided that investors are notified at least 30 days in advance and with the prior consent of the Estonian Financial Supervision and Resolution Authority. By its Management Board resolution dated 31 August 2026, the Estonian Financial Supervision and Resolution Authority has given its consent to the redemption. 

Inbank will prematurely redeem all 450 Inbank AT1 Bonds, each with a nominal value of €10,000 and a total nominal value of €4,500,000. Bondholders will receive the full nominal value of their bonds together with accrued and unpaid interest up to the redemption date. The total amount payable per bond will be €10,070.83.

The redemption payment date will be on 2 November 2026. The list of bondholders will be fixed on 30 October 2026, at the end of the business day of the Nasdaq CSD settlement system (the record date). 

Inbank is a financial technology company with an EU banking license that connects merchants, consumers and financial institutions on its next generation embedded finance platform. Partnering with more than 6,200 merchants, Inbank has 807,000+ active contracts and collects deposits across 7 markets in Europe. Inbank bonds are listed on the Nasdaq Tallinn Stock Exchange.

Additional information:
Styv Solovjov
AS Inbank
Head of Investor Relations
+372 5645 9738
styv.solovjov@inbank.ee

São Paulo, Sept. 28, 2026 (GLOBE NEWSWIRE) — Marfrig Global Foods S.A. (“MBRF”) (B3: MBRF3; ADR Level 1: MBRFY), through its subsidiary, NBM US Holdings, Inc. (“NBM” or the “Offeror”), Banco Bradesco BBI S.A., Banco BTG Pactual S.A. – Cayman Branch, HSBC Securities (USA) Inc., J.P. Morgan Securities LLC and Santander US Capital Markets LLC (the “Dealer Managers”) today announced the commencement of an offer by the Offeror to purchase for cash from each registered holder (each, a “Holder” and, collectively, the “Holders”) any and all of the outstanding 6.625% Senior Notes due 2029 (CUSIP Nos. 62877V AB7; U63768 AB8 / ISIN Nos. US62877VAB71; USU63768AB83) issued by NBM (the “Notes” and the “Offer”, respectively).

The Offer is being made by the Offeror pursuant to the offer to purchase dated September 28, 2026 (the “Offer to Purchase”). The principal purpose of the Offer is to acquire for cash any and all of the outstanding Notes.

Notes validly tendered and not withdrawn prior to the Withdrawal Date (as defined below) will be purchased by the Offeror. The table below summarizes certain payment terms for the Offer:

Title of Security	CUSIP	ISIN	Principal Amount Outstanding	Consideration*
6.625% Senior Notes due 2029	62877V AB7 / U63768 AB8	US62877VAB71 / USU63768AB83	US$467,471,000	US$1,002.50

________________

* Per US$1,000 principal amount of Notes validly tendered and accepted for purchase, excluding Accrued Interest to the Settlement Date.

The Offer will expire at 5:00 p.m., New York City time, on October 2, 2026, unless extended or earlier terminated (such date and time, including as extended or earlier terminated, the “Expiration Date”). The deadline for withdrawing tenders is 5:00 p.m., New York City time, on October 2, 2026 (such date and time, including as extended, the “Withdrawal Date”), unless extended.

The Offeror expects the settlement of accepted Notes to occur, within two business days following the Expiration Date, which is expected to be October 6, 2026 (the “Settlement Date”).

The consideration for each US$1,000 principal amount of Notes validly tendered and not validly withdrawn is US$1,002.50 (the “Consideration”). Holders who validly tender their Notes at or prior to the Expiration Date and whose Notes are purchased in the Offer, will receive the Consideration plus accrued and unpaid interest (the “Accrued Interest”) in respect of their purchased Notes from the last interest payment date to, but excluding, the Settlement Date.

The Offer is conditioned upon, among other things, the consummation or closing on terms satisfactory to NBM of one or more offerings of senior notes by subsidiaries of MBRF and guaranteed by MBRF, NBM,  BRF S.A., Marfrig Holdings (Europe) B.V. and Marfrig Overseas Limited (the “Guarantors”), to be sold in an offering exempt from the registration requirements of the U.S. Securities Act of 1933, as amended (the “Securities Act”) (the “Debt Offering”) (the “Financing Condition”). The Debt Offering is not conditioned upon completion of the Offer. The Offer is not conditioned on any minimum amount of Notes being tendered. No assurance can be given that the Debt Offering will be priced or completed on the terms currently envisioned or at all. Additional conditions to the Offer are described under “Conditions to the Offer” in the Offer to Purchase.

The information and tender agent for the Offer is D.F. King & Co., Inc. (the “Information and Tender Agent”). To contact the Information and Tender Agent, banks and brokers may call +1 (212) 328-8038, and others may call U.S. toll-free: +1 (800) 515-4479. Additional contact information is set forth below.

Banks and Brokers: +1 (212) 328-8038	All others toll free (U.S. only): +1 (800) 515-4479
E-mail: MBRF@dfking.com	Offer website: www.dfking.com/MBRF

Any questions or requests for assistance in relation to the Offer and the Offer to Purchase may be directed to the Dealer Managers at their respective telephone numbers set forth below or, if by any Holder, to such Holder’s broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offer. Requests for additional copies of the Offer to Purchase may be directed to the Information and Tender Agent at the telephone numbers set forth above. Documents relating to the Offer, including the Offer to Purchase, are also available at www.dfking.com/MBRF.

The Dealer Managers for the Offer are:

Banco Bradesco BBI S.A. Av. Presidente Juscelino Kubitschek, 1309, 5th floor São Paulo, SP 04543-011 – Brazil Attn: International Fixed Income Department Tel: +1 (646) 432-6642 E-mail: daniel.fuccillo@bradescobbi.com	Banco BTG Pactual S.A. – Cayman Branch 601 Lexington Avenue, 57th floor New York, NY 10022 Attn: Debt Capital Markets Call Collect: +1 (646) 924-2500 E-mail: ol-dcm@btgpactual.com
HSBC Securities (USA) Inc. 66 Hudson Boulevard New York, NY 10001 Attn: Global Liability Management Group Toll-Free: +1 (888) HSBC-4LM Call Collect: +1(212) 525-5552 E-mail: lmamericas@us.hsbc.com	J.P. Morgan Securities LLC 270 Park Avenue New York, NY 10017 Attn: Latin America Debt Capital Markets Call Collect: +1 (212) 834-4533 Toll-free: +1 (866) 846-2874
Santander US Capital Markets LLC 437 Madison Avenue, 8th floor New York, NY 10022 Attn: Liability Management Group Toll-Free: +1 (855) 404-3636 Call Collect: +1 (212) 940-1442 E-mail: AmericasLM@santander.us

This notice does not constitute or form part of any offer or invitation to purchase, or any solicitation of any offer to sell, the Notes or any other securities in the United States or any other country, nor shall it or any part of it, or the fact of its release, form the basis of, or be relied on or in connection with, any contract therefor. The Offer is made only by and pursuant to the terms of the Offer to Purchase, and the information in this notice is qualified by reference to the Offer to Purchase. None of the Offeror, the Guarantors, the Dealer Managers or the Information and Tender Agent makes any recommendation as to whether Holders should tender their Notes pursuant to the Offer.

This notice to the market does not represent an offer to sell securities or a solicitation to buy securities in the United States or in any other country. The Debt Offering has not been and will not be registered with the Securities and Exchange Commission of Brazil (CVM) and also will not be registered under the Securities Act. Consequently, the Notes issued in the Debt Offering are prohibited from being offered or sold in the United States or to U.S. persons without the applicable registration or exemption from registration required under the Securities Act.

This press release is released for disclosure purposes only, in accordance with applicable law. It does not constitute marketing material and should not be interpreted as advertising an offer to sell or soliciting any offer to buy securities issued by the Offeror or any of the Guarantors.

Forward-Looking Statements

This notice includes and references “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may relate to, among other things, the Offeror’s and the Guarantors’ business strategy, goals and expectations concerning their market position, future operations, margins and profitability.

Although the Offeror and the Guarantors believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect.

The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and trends to differ materially from those made, projected or implied in or by the forward-looking statements depending on a variety of uncertainties or other factors.

The Offeror and the Guarantors undertake no obligation to update any of their forward-looking statements.

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) plans to release its third quarter 2026 financial results on Friday, October 23, 2026, before North American financial markets open. The results will be distributed by newswire and posted at about.rogers.com/investor-relations. Rogers management will host its quarterly teleconference with the investment community to discuss the results and outlook at 8:00 a.m. ET.

A live webcast of the teleconference will be available on the Investor Relations section of Rogers’ website at about.rogers.com/investor-relations. Alternatively, the teleconference can be accessed by dialing 647-361-2258 (1-844-282-4459 toll free Canada/USA). When prompted, callers are required to enter passcode 3793238# for admittance to the call.

An archive of the presentation will be available at this same website following the teleconference. In addition, a telephonic re-broadcast will be available for two weeks following the teleconference by dialing 1-855-669-9658 (toll free Canada/USA) and providing access code 4728600#.

About Rogers:
Rogers is Canada’s communications, sports and entertainment company and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit rogers.com or about.rogers.com/investor-relations.

For further Information:
Investor Relations
1-844-801-4792
investor.relations@rci.rogers.com

WUXI, China, Sept. 28, 2026 (GLOBE NEWSWIRE) — LOBO TECHNOLOGIES LTD. (NASDAQ: LOBO) (“LOBO” or the Company”), an innovative manufacturer of electric mobility products and AI service provider, today announced its entry into the AI‑powered community‑and home-based senior care market through the development and rollout of an integrated platform that combines intelligent mobility, multi‑terminal data collection, AI-powered analytics and community-based senior care services.

Building on its existing capabilities in electric mobility manufacturing and AI data services, LOBO is developing an integrated community‑ and home-based senior care platform. Through intelligent senior mobility devices, health wearables designed to collect health, activity and behavioral data across mobility, home and community settings, this platform is intended to support travel safety, continuous health monitoring and risk identification, while enabling intelligent intervention, coordinated community-based care services and remote family care, thereby forming an integrated AI‑powered senior care operating system.

LOBO’s current product and technology portfolio spans three principals categories: intelligent senior mobility devices; onboard embedded non‑contact vital‑sign sensing solutions and AI application modules to integrate data from health wearables for senior users.

Within LOBO’s broader platform architecture, intelligent senior mobility devices are designed to function not only as transportation tools, but also as connected mobile data terminal. Together with health wearables and onboard sensing technologies, these devices can provide multi‑scenario data relating to users’ health status, physical activity, mobility patterns and travel safety.

The Company’s AI‑powered community senior care operating platform is designed to serve as a central data analytics and service hub connects users, family members, community senior care centers, caregivers and partner healthcare resources. The platform is intended to aggregate health and mobility data collected through connected terminals and apply AI and multimodal data analytics to assess health trends and potential risk signals. Planned and developing functionality also includes care work‑order dispatching, remote family monitoring, AI voice companionship, medication reminders and electronic health record management.

Though this architecture, LOBO is developing a closed-loop service model encompassing “multi-terminal data collection — AI analysis — health and mobility monitoring — community operation — home-based care.” At this stage, the Company is focused on community- and home-based senior care pilot programs and product validation, with the goal of gradually expanding coverage as commercialization progresses.

LOBO believes its model has several differentiated characteristics compared with certain existing senior care technology solutions. Many existing solutions primarily focus on single‑device health tracking, consumer‑oriented health data analysis or institutional care data collection and analytics capabilities across mobility engineering competencies, intellectual property portfolio, industry‑standard development experience, multi‑scenario data collection and analytics capabilities across mobility, home and community settings, and platform operating capabilities to develop an integrated community‑ and home-based senior care platform.

China’s silver economy represents a significant long‑term market opportunity. According to publicly available industry data, the size of China’s silver economy is projected to exceed RMB 30 trillion (approximately $4.47 trillion) by 2035. By the end of 2025, China’s population aged 60 and above had reached approximately 323 million. With most older adults continuing to rely primarily on home‑ and community‑based care, demand for safety monitoring, health‑risk identification, fall detection, mobility assistance and accessible senior care services continue to grow.

To capture such a vast market, LOBO has been investing in intelligent senior mobility and related technologies for several years. Since 2021, the Company has collaborated with the Jiangsu Research Institute of Dalian University of Technology on the integrated research and development (“R&D”) of core hardware and software technology on the intelligent senior mobility. Through these R&D initiatives, LOBO has developed a portfolio of five software copyrights and invention patents covering technologies including advanced driver‑assistance systems for low‑speed vehicles, full‑band cellular and Internet of Things (“IoT”) connectivity, and video interaction applications.

In 2022, the Company, together with the China Electrotechnical Society and other organizations, participated in the development of the Technical Requirements for Wheeled Service Robots with Traffic Assistance Functions (T/CES 161‑2022), contributing to technical specifications for intelligent mobility and service robot applications. These intellectual property assets, engineering capabilities and industry-standard development experience provide a technical foundation for LOBO’s AI-powered senior care platform. Combined with the Company’s capabilities in multimodal data governance, AI dataset processing and physiological signal analysis, LOBO intends to integrate intelligent mobility hardware, sensing technologies, AI analytics and community-based senior care operations into a unified technology and service architecture.

Management views this initiative as a strategic extension of LOBO’s existing capabilities in electric mobility manufacturing, AI technologies and data services, with the objective of developing an ecosystem integrating hardware, data, AI analytics and community-based senior care services. Rather than relying solely on individual senior mobility products, the Company intends to establish multiple connected data and service terminals around senior users, creating an infrastructure through which mobility, health and behavioral data can support ongoing community- and home-based care services.

As LOBO continues to advance pilot deployments, product validation and community‑oriented commercialization, management believes the silver economy business has the potential to become a new long‑term growth opportunity for the Company.

About LOBO TECHNOLOGIES LTD.

LOBO TECHNOLOGIES LTD. (NASDAQ: LOBO) is a manufacturer of electric mobility products and AI service provider. Its product portfolio includes electric bicycles, electric motorcycles, electric tricycles, electric four-wheeler carts, including golf carts and senior mobility vehicles, as well as AI-related products and services.

For more information about the Company, please visit: www.loboebike.com.

For more information about the Company’s Claw AI Agent platform and LoboToken.ai platform, please visit:

Claw AI Agent platform: www.loboaiclaw.com;

LoboToken.ai: www.lobotoken.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “seek,” “will,” and similar expressions. Any statements in this press release that are not statements of historical fact may be considered forward-looking statements.

These forward-looking statements are based on the Company’s current expectations, estimates and projections as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied in such statements.

LOBO’s AI-powered community home elderly-care platform remains at the pilot deployment and commercialization development stage. Certain platform functions and integrations described herein remain under development or are planned for future implementation. The elderly-care industry generally involves long operating cycles, and the Company’s hardware development, product adoption, community commercialization, service execution, regulatory compliance and near-term revenue contribution remain subject to uncertainty.

Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee that such expectations will prove to be correct. Investors are cautioned that actual results may differ materially from anticipated results and are encouraged to review the risk factors that may affect the Company’s future results as set forth in the Company’s annual report on Form 20-F and in other filings with the U.S. Securities and Exchange Commission.

The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

For more information, please contact:

LOBO TECHNOLOGIES LTD.
Zane Xu
Investor Relations Manager
Email: ir@loboai.com

Ascent Investor Relations LLC
Tina Xiao
Tel: +1-646-932-7242
Email: investors@ascent-ir.com

New York, Sept. 28, 2026 (GLOBE NEWSWIRE) — Columbus Acquisition Corp (the “Company”), a blank check company, today announced that it reconvened its Extraordinary General Meeting of the Shareholders (the “Meeting”) and, without conducting any business, adjourned the Meeting to 9:00 a.m. Eastern Time on September 29, 2026 at the offices of Loeb & Loeb LLP, 345 Park Avenue, New York, NY 10154, and virtually via teleconference using the following dial-in information:

Telephone access:
Within the U.S.: and Canada: 1 800-450-7155 (toll-free)
Outside of the U.S. and Canada: +1 857-999-9155 (standard rates apply)
Phone conference ID: 5870682#

The Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on August 19, 2026, including any amendments or supplements thereto (the “Proxy Statement”), including the proposal to approve the proposed business combination with WISeSat.Space Corp. Except for the meeting date and time provided above, the Company’s previously announced information concerning the Meeting remains unchanged.

The record date for determining the Company shareholders entitled to receive notice of and to vote at the Meeting remains the close of business on August 17, 2026 (the “Record Date”). Shareholders as of the Record Date are eligible to vote, even if they have subsequently sold their shares.

If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal.

If you have already submitted a proxy and do not wish to change your vote, you need not take any further action. If you have submitted a proxy and wish to change your vote, you may revoke your proxy at any time before it is exercised at the Meeting as provided in the Proxy Statement. Please note, however, that if your shares are held in street name by a broker or other nominee and you wish to revoke a proxy, you must contact the broker or nominee to revoke any prior voting instructions.

The Company’s shareholders who have questions regarding the adjournment, or the Meeting, or would like to request documents may contact the Company’s proxy solicitor, Advantage Proxy, Inc., at:

Advantage Proxy, Inc. P.O. Box 10904
Yakima, WA 98909
Individuals call toll-free 1-877-870-8565
Banks and brokers call 1-206-870-8565
Email: ksmith@advantageproxy.com

In addition, shareholders who have already submitted a redemption request with respect to the shares held by them may withdraw such request by contacting our transfer agent. If you would like to change or revoke your prior vote on any proposal, or reverse a redemption request, please refer to the Proxy Statement for additional information on how to do so.

About Columbus Acquisition Corp

Columbus Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Columbus is led by Fen “Eric” Zhang, Chairman and Chief Executive Officer, and Jie “Janet” Hu, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries. 

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including but not limited to the date of the Meeting, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Additional Information and Where to Find It

On August 19, 2026, the Company filed a definitive proxy statement with the SEC in connection with its solicitation of proxies for the Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the website maintained by the SEC at www.sec.gov or by contacting the Company’s proxy solicitor.

Participants in the Solicitation

The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above.

Contact

Fen Zhang
Chairman and Chief Executive Officer
Email: eric.zhang@herculescapital.group

Tel: (+1) 949 899 1827 

Independent French health agency ANSES recommends a maximum nicotine limit for all combustible tobacco product; the Company’s supply now includes non-GMO reduced-nicotine tobacco, addressing a key feasibility question for France and the EU

MOCKSVILLE, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), the only low nicotine tobacco company in the world, today highlighted the findings of a scientific assessment published by ANSES, France’s National Agency for Food, Environmental and Occupational Health Safety, which identifies nicotine reduction in combustible tobacco products as a promising public health initiative and points to 22nd Century’s technology as the only commercially available production path for reduced nicotine content combustible cigarettes.

The ANSES report (Referral No. 2025-AST-0038 – Nicotine), commissioned by France’s Directorate General of Health (DGS) and validated on December 5, 2025, concludes that reducing the nicotine content of cigarettes could be an effective tool in the fight against smoking, citing randomized controlled trials showing that reduced-nicotine cigarettes limit addiction and cigarette consumption and can facilitate abstinence when combined with nicotine replacement therapy and professional support. The report recommends that any maximum nicotine limit be applied to all combustible tobacco products, conventional cigarettes, rolling tobacco and cigars alike, and that the measure be considered at the European Union level, including through the ongoing revision of Directive 2014/40/EU on tobacco products.

The report’s reference standard for very-low-nicotine production

In its assessment of international experience, the report notes that the only very low nicotine cigarettes (VLNC’s) currently available rely on low-nicotine tobacco produced through plant science and describes 22nd Century’s approach as the only currently in commercial use in its VLN^® and Pinnacle VLN^® cigarettes. The report further documents the Company’s regulatory record: FDA authorization of the VLN product line in December 2019, and in December 2021 the first-ever Modified Risk Tobacco Product (MRTP) designation for combustible cigarettes, authorizing 22nd Century as the first cigarette manufacturer to use the claim “Helps reduce nicotine consumption.” The Company has also supplied the Spectrum research cigarette line to the U.S. scientific community in partnership with FDA, the National Institute on Drug Abuse (NIDA), the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) since 2011, and in May 2026 the FDA filed the Company’s MRTP renewal applications for VLN King and VLN Menthol King for scientific review.

Non-GMO reduced-nicotine tobacco now available for France and the EU

The ANSES report raises the question of how reduced nicotine products would fit within French and European rules on genetically modified organisms. 22nd Century has expanded its technology platform to include reduced-nicotine tobacco produced without genetic modification. 22^nd Century’s non-GMO low nicotine tobacco has been sourced at commercial scale and is available to support an initiative like the one contemplated in France or across the broader European Union. This means the nicotine-cap scenario described in the report could be supplied without reliance on genetically modified tobacco, removing a perceived key implementation barrier of the reduced nicotine standard.

Alignment with the WHO Framework Convention on Tobacco Control

A maximum nicotine standard for combustible products, as recommended by ANSES, would operate squarely within the framework of the WHO Framework Convention on Tobacco Control (WHO FCTC), to which France and all EU Member States are parties. Regulation of the product itself, reducing the addictive potential of combustible tobacco, complements the demand-reduction and supply measures the Convention establishes and advances the goal of protecting public health policies from commercial influences on consumption.

A multi-billion-euro market would convert to reduced-nicotine products

Under a nicotine-cap rule of the kind ANSES recommends, the standard would apply to all combustible tobacco products sold in France, converting what is today an estimated to be over €20 billion annual retail market into a very-low-nicotine market. Accounting for the transition dynamics the ANSES report itself identifies, displacement to illicit trade, substitution to other nicotine products such as e-cigarettes, and reduced cigarettes-per-day among remaining smokers, the Company estimates the sustainable legal market at approximately €8-13 billion at retail over the first three to five years following implementation. However, as only a small fraction of the retail price reaches manufacturers after French excise duties and VAT, success under this scenario depends on the supply of reduced-nicotine tobacco at scale, a role 22nd Century’s expanded platform, including non-GMO reduced-nicotine tobacco, is positioned to fulfill.

European policy window

The European Commission launched a call for evidence on May 18, 2026 as part of the announced revision of the EU tobacco control framework, with legislative proposals widely expected to be put forward before the end of 2026. The ANSES report explicitly frames this revision as the opportunity to create a legal framework for reduced-nicotine tobacco products across the EU single market, harmonized to limit cross-border circumvention.

“The ANSES report is a significant validation of the work our Company has pursued for almost three decades. A sovereign public health agency, after a critical review of the global evidence , has concluded that reducing nicotine in combustible products is among the best-supported interventions in the scientific literature, and has identified the approach we pioneered as the one currently available at commercial scale. With reduced-nicotine tobacco now also sourced and available without genetic modification, we are prepared to supply an initiative like France’s in France or across the European Union.” said Larry Firestone, Chief Executive Officer of 22nd Century Group.

“With VLN^® products now commercially available in 23 U.S. states, we are seeing a growing number of consumers adopt the platform and purchase through our retail channels, with sales growing month over month. Our reduced nicotine VLN^® cigarette solution is now gaining recognition in Europe as well. Interested parties and prospective partners across multiple European countries have reached out to the Company, and we are actively evaluating these markets and how we can best serve them,” Firestone continued.

22nd Century Group remains focused on advancing tobacco harm reduction through its FDA-authorized VLN^® product platform and its reduced-nicotine tobacco supply, and looks forward to contributing constructively and transparently to the policy discussions ahead in France and the wider European Union.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the Tobacco Harm Reduction and Nicotine Reduction Movements by enabling smokers to take control of their nicotine consumption. 

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our-high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement. 

Our Products 

We created our flagship product, the VLN^® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN^® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption. 

VLN^® and Helps You Smoke Less^® are registered trademarks of 22nd Century Limited LLC. 

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube. 

Learn more about VLN^® at tryvln.com. 

Cautionary Note Regarding Forward-Looking Statements 

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our expectations regarding regulatory enforcement, including our ability to receive authorization or approval for new products, and (ii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Reports on Form 10-Q filed May 7, 2026 and August 14, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. 

Investor Relations & Media Contact 
Daniel Otto
Chief Financial Officer & Investor Relations 
22nd Century Group 
investorrelations@xxiicentury.com